Citations (11)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Kokuvi Atsou, Larry Ereshefsky, Mélanie Brignone, Natalya Danchenko, Françoise Diamand, Lisa Mucha, Maëlys Touya, Russell Becker & Clément François. (2021) Cost-effectiveness of vortioxetine compared with levomilnacipran and vilazodone in patients with major depressive disorder switching from an initial antidepressant. Expert Review of Pharmacoeconomics & Outcomes Research 21:1, pages 29-42.
Read now
Read now
Gang Wang, Kun Zhao, Caroline Reynaud-Mougin, Henrik Loft, Hongye Ren, Hanne-Lise F. Eriksen & Anders Ettrup. (2020) Successfully treated patients with vortioxetine versus venlafaxine: a simplified cost-effectiveness analysis based on a head-to-head study in Asian patients with major depressive disorder. Current Medical Research and Opinion 36:5, pages 875-882.
Read now
Read now
Michael Cronquist Christensen & Vicki Munro. (2018) Cost per successfully treated patient for vortioxetine versus duloxetine in adults with major depressive disorder: an analysis of the complete symptoms of depression and functional outcome. Current Medical Research and Opinion 34:4, pages 593-600.
Read now
Read now
Erkki Soini, Taru Hallinen, Mélanie Brignone, Rosanne Campbell, Françoise Diamand, Sandrine Cure, Maria Aalto-Setälä, Natalya Danchenko, Hannu Koponen & Katarzyna Kolasa. (2017) Cost-utility analysis of vortioxetine versus agomelatine, bupropion SR, sertraline and venlafaxine XR after treatment switch in major depressive disorder in Finland. Expert Review of Pharmacoeconomics & Outcomes Research 17:3, pages 293-302.
Read now
Read now
Articles from other publishers (7)
Chayan K. Manna, Rajeev Ranjan, Pankaj Kumar, Shamshad Ahmad & Santanu Nath. (2023) Effect of vortioxetine versus venlafaxine on cognitive functions in adults with major depressive disorder: A randomized-controlled trial. Indian Journal of Psychiatry 65:8, pages 815-824.
Crossref
Crossref
Fang Li, Frederike Jörg, Xinyu Li & Talitha Feenstra. (2022) A Promising Approach to Optimizing Sequential Treatment Decisions for Depression: Markov Decision Process. PharmacoEconomics 40:11, pages 1015-1032.
Crossref
Crossref
Juliane Andrea Duevel, Lena Hasemann, Luz María Peña-Longobardo, Beatriz Rodríguez-Sánchez, Isaac Aranda-Reneo, Juan Oliva-Moreno, Julio López-Bastida & Wolfgang Greiner. (2020) Considering the societal perspective in economic evaluations: a systematic review in the case of depression. Health Economics Review 10:1.
Crossref
Crossref
Takeshi Inoue, Kiyofumi Sasai, Tadayuki Kitagawa, Akira Nishimura & Isao Inada. (2019) Randomized, double‐blind, placebo‐controlled study to assess the efficacy and safety of vortioxetine in Japanese patients with major depressive disorder. Psychiatry and Clinical Neurosciences 74:2, pages 140-148.
Crossref
Crossref
Erik J. GroesslSteven R. TallyNaomi HilleryAlejandra MacielJorge A. Garces. (2018) Cost-Effectiveness of a Pharmacogenetic Test to Guide Treatment for Major Depressive Disorder. Journal of Managed Care & Specialty Pharmacy 24:8, pages 726-734.
Crossref
Crossref
Estela Salagre, Iria Grande, Brisa Solé, Jose Sanchez-Moreno & Eduard Vieta. (2018) Vortioxetine: A new alternative for the treatment of major depressive disorder. Revista de Psiquiatría y Salud Mental (English Edition) 11:1, pages 48-59.
Crossref
Crossref
Estela Salagre, Iria Grande, Brisa Solé, Jose Sanchez-Moreno & Eduard Vieta. (2018) Vortioxetina: una nueva alternativa en el trastorno depresivo mayor. Revista de Psiquiatría y Salud Mental 11:1, pages 48-59.
Crossref
Crossref